Clinical and molecular characteristics of non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

Date publication

juillet 2017

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Dr DEBIEUVRE Didier

Tous les auteurs :
Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28945865

Résumé

EGFR mutations cause inconsistent response to EGFR tyrosine kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR -mutated NSCLC collected in the Biomarkers France database.

Mots clés

epidemiology, epidermal growth factor receptor gene (EGFR) mutations, non-small-cell lung cancer (NSCLC), tyrosine-kinase inhibitors (TKI)

Référence

Ann. Oncol.. 2017 Jul;: